Pharmaceutical Technology Europe - November 2012 - (Page 5)

NEWS BITES Europe Establishes First Facility for Cell- Novasep to Build the World’s Largest Chromatography Plant Based Therapeutics A consortium in France has announced the establishment of Europe’s first ever industrial manufacturing facility dedicated to the large-scale production of novel, advanced cell-based therapy medicinal products. The plant, located in Les Ulis, near Paris, at the site of the French biopharmaceutical company LFB Biotechnologies, has the capacity to produce 3000 to 5000 therapeutic batches per year. The facility will be used for innovative R&D projects on autologous and allogeneic cell therapies that are progressing from early clinical research stage up to industrial production. The facility project, known as C4C, is coordinated by CELLforCURE, a subsidiary of LFB Biotechnologies http://www.pharmtech.com/pharmtech/News/Europe-Establishes-First-Facilityfor-Cell-Based-T/ArticleStandard/Article/detail/793994?contextCategoryId=35097 Novasep will be investing EUR 30 million ($39 million) to build what will be the world’s largest chromatography plant for the production of large volumes of commercial APIs. The plant will be built on Novasep’s existing site in Mourenx, France, and is expected to be operational and validated within 18 months. The plant will enable the production of a highly purified API from a complex mixture. In addition, the systems will integrate sophisticated solvent recovery systems for the recycling of 99.9% of solvents. http://www.pharmtech.com/pharmtech/News/Novasep-to-Build-the-WorldsLargest-Chromatography/ArticleStandard/Article/detail/792811?contextCatego ryId=35097 Dr. Reddy’s Plans to Acquire OctoPlus Dr. Reddy’s is planning to acquire the specialty injectable company OctoPlus for approximately EUR 27.4 million. The offer of EUR 0.52 per share represents a premium of OctoPlus’ most recent closing price and was unanimously approved by the OctoPlus board. Dr. Reddy’s has been following the activities of OctoPlus for some time and is particularly interested in OctoPlus’ expertise in drug formulation and difficult-to-formulate injectables. http://www.pharmtech.com/pharmtech/News/Dr-Reddys-Announces-Plans-toAcquire-OctoPlus-for-/ArticleStandard/Article/detail/793597?contextCategoryId=35097 Patheon to Acquire Banner Pharmacaps Patheon will acquire softgel-specialist company Banner Pharmacaps, based in North Carolina in the US, for $255 million. The acquisition will provide Patheon with several new products, technologies and facilities, and is also in line with the company’s intention to further develop its oral dosage development and manufacturing services. According to a press statement, Banner Pharmacaps is the second largest pharmaceutical business in the world focused on developing softgel formulations. http://www.pharmtech.com/pharmtech/News/Patheon-to-Acquire-BannerPharmacaps/ArticleStandard/Article/detail/794745?contextCategoryId=35097 2 EXTRACTABLES & LEACHABLES 9 ALZHEIMER’S DISEASE 5 NEWS 10 BLOGS 7 QUALITY BY DESIGN 11 TECHNOLOGY 8 BIOSIMILAR mAbS 12 STAFF http://www.pharmtech.com/pharmtech/News/Novasep-to-Build-the-Worlds-Largest-Chromatography/ArticleStandard/Article/detail/792811?contextCategoryId=35097 http://www.pharmtech.com/pharmtech/News/Europe-Establishes-First-Facility-for-Cell-Based-T/ArticleStandard/Article/detail/793994?contextCategoryId=35097 http://www.pharmtech.com/pharmtech/News/Dr-Reddys-Announces-Plans-to-Acquire-OctoPlus-for-/ArticleStandard/Article/detail/793597?contextCategoryId=35097 http://www.pharmtech.com/pharmtech/News/Patheon-to-Acquire-Banner-Pharmacaps/ArticleStandard/Article/detail/794745?contextCategoryId=35097

Table of Contents for the Digital Edition of Pharmaceutical Technology Europe - November 2012

Pharmaceutical Technology Europe - November 2012
Contents
Cover Story: Examining the Growing Challenge of Extractables & Leachables: An Industry Roundtable
News Bites
Applying Quality by Design for Extended-Release Hydrophilic Matrix Tablets
EU Sets Guidelines for Biosimilar Monoclonal Antibodies
Will Europe Discourage the Launch of New Alzheimer’s Drugs?
Blogs: Roche Under Investigation; Q3 Financial Reports
Top IT Technologies

Pharmaceutical Technology Europe - November 2012